# US 6,727,067 B2 · Methods for the analysis of non-proteinaceous components using a protease from a Bacillus strain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,067 B2
- Document ID: US6727067B2
- Status: Granted
- Kind: B2
- Application number: 10/007,389
- Filed: 2001-10-29
- Published: 2003-09-04
- Granted: 2004-04-27
- Earliest claimed: 2001-10-29
- Assignees: Roche Molecular Systems, Inc.
- Inventors: Eberhard Russman; Thomas Meier; Ranier Schmuck; Johnny Staepels; Uwe Wehnes
- Web page: https://patentgrep.com/patent/US6727067B2

## CPC

- C12Q 1/37: involving peptidase or proteinase
- C12N 9/54: bacteria being Bacillus
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Y 304/21062: Subtilisin (3.4.21.62)
- G01N 2333/32: from Bacillus (G)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to a method for the analysis of a (at least one) target non-proteinaceous component of a mixture of non-proteinaceous and proteinaceous components derived from a biological sample using a protease from a Bacillus strain. The invention further relates to a method for the analysis of a (at least one) target nucleic acid component of a mixture of non-proteinaceous components, which comprise nucleic acids, and proteinaceous components whereby the mixture is derived from a biological sample comprising the steps of incubating the mixture with a (at least one) protease from a Bacillus strain, optionally amplifying the (at least one) target nucleic acid component, and determining or detecting the (at least one) target nucleic acid component.

## Claims

### Claim 1

A method for the analysis of a target non-proteinaceous component of a mixture of non-proteinaceous and proteinaceous components derived from a biological sample comprising the steps of
a) incubating the mixture with a protease comprising an amino acid sequence which is at least 80% identical to SEQ ID NO: 1; and
b) analyzing the target non-proteinaceous component.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the amino acid sequence of the protease is identical to SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the amino acid sequence of protease comprises SEQ ID NO:1, a proteolytic derivative thereof having protease activity or SEQ ID NO:2.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the amino acid sequence of the protease is encoded by a nucleic acid comprising the nucleic acid sequence SEQ ID NO:3 or a part thereof or a degenerate version of either.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the biological sample is a fluid from the human or animal body.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the biological sample is blood, blood plasma, blood serum or urine.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the biological sample comprises bacterial cells, eukaryotic cells, viruses or mixtures thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein after the incubation step the target non-proteinaceous component is bound to a material with an affinity thereto, optionally washed and optionally released from the material with an affinity thereto.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the non-proteinaceous component comprises a nucleic acid.

### Claim 10 (depends on 9)

The method according to claim 9 wherein the nucleic acid comprises DNA or RNA or both.

### Claim 11

A method for the analysis of a target nucleic acid component of a mixture comprising the target nucleic acid component, and a proteinaceous component whereby the mixture is derived from a biological sample, which method comprises the steps of
a) incubating the mixture with a protease comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 1,
b) optionally amplifying the target nucleic acid component, and
c) determining or detecting the target nucleic acid component, wherein the target nucleic acid component is analyzed.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the amino acid sequence of the protease is identical to SEQ ID NO: 1.

### Claim 13 (depends on 11)

The method according to claim 11 wherein the amino acid sequence of the protease comprises SEQ ID NO:1, a proteolytic derivative thereof having protease activity or SEQ ID NO:2.

### Claim 14 (depends on 11)

The method according to claim 11 wherein the amino acid sequence of the protease is encoded by a nucleic acid comprising the nucleic acid sequence SEQ ID NO:3 or a part thereof or a degenerate version of either.

### Claim 15 (depends on 11)

The method according to claim 11 wherein the biological sample is a fluid from a human or animal body.

### Claim 16 (depends on 11)

The method according to claim 11 wherein the biological sample is blood, blood plasma, blood serum or urine.

### Claim 17 (depends on 11)

The method according to claim 11 wherein the target nucleic acid component comprises DNA or RNA or both.

### Claim 18 (depends on 17)

The method according to claim 17 wherein the DNA or RNA or both is derived from a virus or a microorganism.

### Claim 19 (depends on 18)

The method according to claim 18 wherein the virus is hepatitis B virus, hepatitis C virus or human immunodeficiency virus.

### Claim 20 (depends on 11)

The method according to claim 11 wherein the target nucleic acid component is amplified with the polymerase chain reaction.

### Claim 21 (depends on 11)

The method according to claim 11 wherein after step a) the target nucleic acid component is bound to a material with an affinity to nucleic acids, optionally washed and optionally released from the material.

### Claim 22 (depends on 21)

The method according to claim 21 wherein the material with an affinity to nucleic acids comprises a material with a silica surface.

### Claim 23 (depends on 22)

The method according to claim 22 wherein the material with a silica surface is a glass.

### Claim 24 (depends on 21)

The method according to claim 21 wherein the material with an affinity to nucleic acids is a composition comprising magnetic glass particles.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method according to any of the claims 1 to 24, wherein the analysis is a diagnosis of a disease or a pathogen.

### Claim 26

A kit comprising a protease comprising an amino acid sequence, which is at least 80% identical to SEQ ID NO:1, and a material with an affinity to nucleic acids, wherein the material with an affinity to nucleic acids comprises a material with a silica surface.

### Claim 27 (depends on 26)

The kit according to claim 26 wherein the material with a silica surface is a glass.

### Claim 28

A kit comprising a protease comprising an amino acid sequence, which is at least 80% identical to SEQ ID NO:1, and a material with an affinity to nucleic acids, wherein the material with an affinity to nucleic acids is a composition comprising magnetic glass particles.

### Claim 29 (depends on 27)

The kit according to claim 27 wherein the kit additionally comprises a lysis buffer, a washing buffer and an elution buffer.

### Claim 30

A composition comprising a protease comprising an amino acid sequence which is at least 80% identical to SEQ ID NO: 1, in a solution 10 mM Tris acetate pH 5.5, 5 mM calcium acetate, 1 mM EDTA, and 50% (V/V) Glycerin.

### Claim 31 (depends on 30)

The composition according to claim 30 wherein the amino acid sequence of the protease is identical to SEQ ID NO: 1.

### Claim 32 (depends on 30)

The composition according to claim 30 wherein the amino acid sequence of the protease comprises SEQ ID NO:1, a proteolytic derivative thereof having protease activity or SEQ ID NO:2.

### Claim 33 (depends on 30)

The composition according to claim 30 wherein the amino acid sequence of the protease is encoded by a nucleic acid comprising the nucleic acid sequence SEQ ID NO:3 or a part thereof or a degenerate version of either.
